A Study to Assess the Relative Bioavailability of Oral ABBV-932 in Healthy Adult Participants

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

RECRUITING

Clinical Phase

PHASE1

Total Enrollment

42 participants

Study Classification

INTERVENTIONAL

Study Start Date

2025-02-26

Study Completion Date

2026-04-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This study will assess the relative bioavailability and effect of food on pharmacokinetics of ABBV-932 oral administration in healthy adult participants.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

A Study to Assess the Relative Bioavailability of Immediate Release Formulations of ABBV-903 in Healthy Adult Participants

NCT05836506

Healthy Volunteer

COMPLETED PHASE1

A Study to Assess the Relative Bioavailability of Three Immediate-Release Tablet Formulations of ABBV-903 in Healthy Adult Volunteers

NCT06078202

Healthy Volunteers

WITHDRAWN PHASE1

A Study to Assess Relative Bioavailability and Food Effect of ABBV-668 Extended-Release Formulations in Adult Participants

NCT06477926

Healthy Volunteers

COMPLETED PHASE1

A Study to Assess the Safety, Tolerability, and Pharmacokinetics of ABBV-1088 Oral Dose in Healthy Adult Participants.

NCT06414798

Healthy Volunteers

COMPLETED PHASE1

A Mass Balance Study of Oral [14C] ABBV-932 in Healthy Adult Male Participants

NCT06953934

Healthy Volunteer

NOT_YET_RECRUITING PHASE1

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Healthy Volunteer

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

CROSSOVER

Primary Study Purpose

BASIC_SCIENCE

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

ABBV-932: Arm A

Participants will receive a single dose of ABBV-932 Arm A on day 1 under fasting conditions.

Group Type EXPERIMENTAL

ABBV-932

Intervention Type DRUG

Oral Capsule

ABBV-932: Arm B

Participants will receive a single dose of ABBV-932 Arm B on day 1 under fasting conditions.

Group Type EXPERIMENTAL

ABBV-932

Intervention Type DRUG

Oral tablet

ABBV-932: Arm C

Participants will receive a single dose of ABBV-932 Arm C on day 1 under fasting conditions.

Group Type EXPERIMENTAL

ABBV-932

Intervention Type DRUG

Oral Capsule

ABBV-932: Arm D

Participants will receive a single dose of ABBV-932 Arm D on day 1 with a high-fat meal.

Group Type EXPERIMENTAL

ABBV-932

Intervention Type DRUG

Oral tablet

ABBV-932: Arm E

Participants will receive a single dose of ABBV-932 Arm E on day 1 with a high-fat meal.

Group Type EXPERIMENTAL

ABBV-932

Intervention Type DRUG

Oral Capsule

ABBV-932: Arm F

Participants will receive a single dose of ABBV-932 Arm F on day 1 under fasting conditions.

Group Type EXPERIMENTAL

ABBV-932

Intervention Type DRUG

Oral Capsule

ABBV-932: Arm G

Participants will receive a single dose of ABBV-932 Arm G on day 1 with a high-fat meal.

Group Type EXPERIMENTAL

ABBV-932

Intervention Type DRUG

Oral Capsule

ABBV-932: Arm H

Participants will receive a single dose of ABBV-932 Arm H on day 1 under fasting conditions.

Group Type EXPERIMENTAL

ABBV-932

Intervention Type DRUG

Oral Capsule

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

ABBV-932

Oral Capsule

Intervention Type DRUG

ABBV-932

Oral tablet

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Body Mass Index (BMI) ≥ 18.0 to ≤ 32.0 kg/m\^2 after rounding to the tenths decimal at the time of screening and upon initial confinement. BMI is calculated as weight in kg divided by the square of height measured in meters.
* A condition of general good health, based upon the results of a medical history, physical examination, vital signs, laboratory profile, and a 12-lead ECG

Exclusion Criteria

* History of epilepsy, any clinically significant cardiac, respiratory (except mild asthma as a child), renal, hepatic, gastrointestinal, hematologic or psychiatric disease or disorder, or any uncontrolled medical illness.
* History of any clinically significant sensitivity or allergy to any medication or food.

Minimum Eligible Age

18 Years

Maximum Eligible Age

65 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes